Pexiganan Topical Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical formulations of pexiganan are chemically and physically unstable, making them unsuitable for long-term storage and effective treatment of wound infections, particularly in diabetic foot ulcers, where resistance to antibiotics is a significant concern.
Innovation Solution
A stable topical formulation of pexiganan is achieved by combining polyoxyethylen(20)-sorbitan-monostearat (Tween 60) as a hydrophilic surfactant and sorbitanmonostearat (Span 60) as a hydrophobic surfactant, with specific HLB values and ratios, along with other excipients like propylene glycol, stearyl alcohol, and EDTA, to enhance both chemical and physical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pexiganan is formulated as a topical cream, then it provides effective treatment of wound infections with low resistance potential, but the formulation becomes chemically and physically unstable during long-term storage
Solution Approach 1:
The patent applies parameter changes by systematically adjusting the HLB values of surfactants, pH levels, and concentrations of excipients to achieve a stable formulation. Specifically, the invention uses a hydrophilic surfactant with HLB 12-17 and a hydrophobic surfactant with HLB 3.5-5.5, maintaining a blended HLB between 12.5-14.5, and controls pH between 4.0-6.0 to prevent degradation while maintaining effectiveness.
Solution Approach 2:
The patent employs composite materials by combining multiple surfactants with complementary properties (hydrophilic and hydrophobic), along with excipients like propylene glycol, stearyl alcohol, and EDTA, to create a synergistic formulation that provides both stability and effectiveness. This composite approach allows the formulation to maintain drug concentration above 90% after long-term storage.
2Reliability
If systemic antibiotics are used to treat wound infections, then broad-spectrum antimicrobial activity is achieved, but antibiotic resistance develops and side effects occur in diabetic patients
Solution Approach 1:
The patent extracts the antimicrobial activity from systemic antibiotics and relocates it to a topical peptide agent (pexiganan) that acts locally at the wound site. This eliminates the need for systemic administration, avoiding the harmful effects of antibiotic resistance development and systemic side effects while maintaining broad-spectrum antimicrobial activity against Gram-positive and Gram-negative organisms.
3Object-generated harmful factors
If topical formulations are developed for pexiganan, then localized treatment with reduced resistance potential is achieved, but the formulations suffer from poor chemical and physical stability
Solution Approach 1:
The patent introduces surfactants as intermediary substances that mediate between pexiganan and the formulation vehicle. The hydrophilic surfactant (HLB 12-17) and hydrophobic surfactant (HLB 3.5-5.5) act as intermediaries to solubilize the peptide, prevent aggregation, and maintain physical stability, while excipients like EDTA and propylene glycol further stabilize the chemical structure during storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains a drug concentration above 90% after long-term storage, preventing degradation and ensuring effective treatment of wound infections with improved patient compliance and reduced resistance risks.
Implementation Method 1
A stable topical formulation of pexiganan is achieved by combining polyoxyethylen(20)-sorbitan-monostearat (Tween 60) as a hydrophilic surfactant and sorbitanmonostearat (Span 60) as a hydrophobic surfactant
Implementation Method 2
The formulations comprise a hydrophilic surfactant having an HLB value between 12 and 17 and a hydrophobic surfactant having an HLB value between 3.5 and 5.5
Data Source
AI summary
The invention provides chemically and physically stable topical formulations of pexiganan, and methods of preparing the same.